Cargando…

Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation

Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins αvβ3, αvβ5 and α5β1. It was developed by us in the early 90s by a novel pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mas-Moruno, Carlos, Rechenmacher, Florian, Kessler, Horst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267166/ https://www.ncbi.nlm.nih.gov/pubmed/21269250 http://dx.doi.org/10.2174/187152010794728639

Ejemplares similares

Tumor Targeting via Integrin Ligands
por: Marelli, Udaya Kiran, et al.
Publicado: (2013)

Gene expression profiling of the anti-glioma effect of Cilengitide
por: Onishi, Manabu, et al.
Publicado: (2013)

In vitro and in vivo drug disposition of cilengitide in animals and human
por: Dolgos, Hugues, et al.
Publicado: (2016)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

Towards the cell-instructive bactericidal substrate: exploring the combination of nanotopographical features and integrin selective synthetic ligands
por: Fraioli, Roberta, et al.
Publicado: (2017)

The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia
por: Nikuei, Pooneh, et al.
Publicado: (2015)

A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins
por: Kapp, Tobias G., et al.
Publicado: (2017)

In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines
por: Lautenschlaeger, Tim, et al.
Publicado: (2013)

The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
por: Guan, Yelan, et al.
Publicado: (2023)

Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12
por: Bid, Hemant K., et al.
Publicado: (2012)

Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity
por: Placencio, Veronica R., et al.
Publicado: (2015)

Cilengitide Inhibits Neovascularization in a Rabbit Abdominal Aortic Plaque Model by Impairing the VEGF Signaling
por: Zhu, Fawang, et al.
Publicado: (2021)

Design, synthesis and evaluation of novel tetrahydropyridothienopyrimidin-ureas as cytotoxic and anti-angiogenic agents
por: Motahari, Rasoul, et al.
Publicado: (2022)

SUN-LB054 Cilengitide Reverts Thyroid Hormones Effects in Bexarotene Treatment of Breast Cancer Cells
por: Díaz Albuja, Johanna, et al.
Publicado: (2019)

Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
por: Alalami, Huda, et al.
Publicado: (2023)

Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells
por: Jeong, Jisu, et al.
Publicado: (2022)

Effects of cilengitide derivatives on TGF-β1-induced epithelial-to-mesenchymal transition and invasion in gefitinib-resistant non-small cell lung cancer cells
por: Seo, Yujin, et al.
Publicado: (2023)

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2008)

Pre-emptive and therapeutic value of blocking bacterial attachment to the endothelial alphaVbeta3 integrin with cilengitide in sepsis
por: Garciarena, Carolina D., et al.
Publicado: (2017)

Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model
por: Pan, Xin, et al.
Publicado: (2022)

Evaluating Angiogenic Potential of Small Molecules Using Genetic Network Approaches
por: Das, Anusuya, et al.
Publicado: (2018)

Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase
por: Colombo, Cinzia, et al.
Publicado: (2018)

Cyclobutanes in Small‐Molecule Drug Candidates
por: van der Kolk, Marnix R., et al.
Publicado: (2022)

Cilengitide inhibits osteoclast adhesion through blocking the α(v)β(3)-mediated FAK/Src signaling pathway
por: Guo, Dan-yang, et al.
Publicado: (2023)

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
por: Manegold, Christian, et al.
Publicado: (2012)

Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients
por: Cedra, Susan, et al.
Publicado: (2017)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
por: Jeong, Jisu, et al.
Publicado: (2021)

Interface Immobilization Chemistry of cRGD-based Peptides Regulates Integrin Mediated Cell Adhesion
por: Pallarola, Diego, et al.
Publicado: (2014)

Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
por: Chatterjee, Subhojyoti, et al.
Publicado: (2012)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Tian, Wentao, et al.
Publicado: (2020)

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties
por: Soomro, Shahid, et al.
Publicado: (2011)

Design of Anti-Angiogenic Peptidomimetics and Evaluation their Biological Activity by In Vitro Assays
por: Ghadam, Mona, et al.
Publicado: (2020)

Designing fisetin nanocrystals for enhanced in cellulo anti-angiogenic and anticancer efficacy()
por: Ma, Panpan, et al.
Publicado: (2022)

Nonlinear Adaptive Optimal Controller Design for Anti-Angiogenic Tumor Treatment
por: Nath, Nitendra, et al.
Publicado: (2023)

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer’s disease
por: Liang, Meihao, et al.
Publicado: (2022)

Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
por: Koes, David, et al.
Publicado: (2012)

Synthesis, Anti-Tumor and Anti-Angiogenic Activity Evaluations of Asiatic Acid Amino Acid Derivatives
por: Jing, Yue, et al.
Publicado: (2015)

Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation
por: Zhang, Qian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i883e1nomh63on0o43rlt627rc